Key Insights

Highlights

Treatment Research

5 treatments under study, led by Cart Therapy In Relapsedrefractory Multiple Myeloma

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

66.7%

2 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results0

Data Visualizations

Phase Distribution

3Total
Phase 1 (2)
Phase 2 (1)

Trial Status

Terminated2
Unknown1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04412707Phase 2TerminatedPrimary

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

NCT02684617Phase 1Terminated

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

NCT03778346Phase 1UnknownPrimary

Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

Showing all 3 trials

Research Network

Common Treatments

  • Cart Therapy In Relapsedrefractory Multiple Myeloma1
  • Dinaciclib1
  • Dexamethasone1
  • Melphalan1
  • Pembrolizumab1

Active Sponsors

  • The Sixth Affiliated Hospital of Wenzhou Medical University1
  • Oncopeptides AB1
  • Zhejiang Qixin Biotech1
  • Merck Sharp & Dohme LLC1

Top Investigators

Related Conditions

  • Rrdlbcl1
  • Rrcll1

Activity Timeline